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AbstrAct:
Cancer cells re-program their metabolic machinery in order to satisfy their 
bioenergetic and biosynthetic requirements. A critical aspect of the re-programming 
of cancer cell metabolism involves changes in the glycolytic pathway (referred to 
as the “Warburg effect”). As an outcome of these changes, much of the pyruvate 
generated via the glycolytic pathway is converted to lactic acid, rather than being 
used to produce acetyl-CoA and ultimately, the citrate which enters the citric acid 
cycle. In order to compensate for these changes and to help maintain a functioning 
citric acid cycle, cancer cells often rely on elevated glutamine metabolism. 
Recently, we have found that this is achieved through a marked elevation of 
glutaminase activity in cancer cells. Here we further consider these findings and 
the possible mechanisms by which this important metabolic activity is regulated.
rho GtPAses And cellulAr 
metAbolism in mAliGnAnt 
trAnsformAtion
Our initial efforts to identify novel small molecule 
inhibitors that block malignant transformation were 
directed at Rho family GTPase-signaling pathways. There 
were a number of reasons for this, perhaps foremost being 
that our laboratory has been studying the small GTPase 
Cdc42, as well as the closely related proteins Rac, and 
RhoA, and their signaling partners for a number of years. 
Signals originating from members of this GTPase family 
have been shown to be important for a broad array of cellular 
processes ranging from actin cytoskeletal rearrangements 
to cell polarity, migration, and cell-cycle progression [1]. 
However, these GTPases have also been implicated in a 
variety of diseases and developmental disorders, with a 
number of lines of evidence linking Rho family members 
to cancer [2]. For example, their hyper-activation as it 
occurs either through mutations or the de-regulation 
of their upstream activators, i.e. guanine nucleotide 
exchange factors which catalyze the exchange of GDP 
for GTP on these GTPases (such as members of the Dbl 
family of oncoproteins), results in cellular transformation 
[3,4]. Cells expressing constitutively active forms of Rho 
GTPases have been shown to be capable of growing under 
conditions of serum deprivation and in the absence of a 
substratum (i.e. anchorage-independent growth), as well 
as inducing tumor formation when injected into immuno-
compromised mice [5-7]. The over-expression of Rho 
GTPases has been reported in tumors of the colon, lung, 
and in advanced stage breast cancers, in testicular germ 
cell and urinary tract tumors, and in pancreatic cancer [8-
14]. Two members of the family, RhoA and RhoC, have 
been implicated in metastasis [15-18], and the expression 
of the Rho-GTPase-activating protein (Rho-GAP) DLC1 
(for Deleted in Liver Cancer 1) is suppressed in liver 
cancer tissue and in a number of other cancers [19,20]. 
Thus, collectively these findings make the Rho GTPases 
and their regulatory proteins attractive candidates for 
targets of intervention in human cancer.
A surPrisinG connection   
between rho GtPAse-induced 
cellulAr trAnsformAtion And 
cellulAr metAbolic Activity 
We have recently discovered a new role for Rho 
GTPases in cancer progression through a previously 
unappreciated connection to cellular metabolism [21]. Oncotarget 2010; 1:  734 - 740 735 www.impactjournals.com/oncotarget
In particular, we have found that the hyper-activation of 
Cdc42 as well as related Rho GTPases (e.g. Rac1, RhoA 
and RhoC) signals the activation of a mitochondrial 
enzyme, glutaminase, that plays a key role in glutamine 
metabolism by hydrolyzing glutamine to glutamate and 
ammonia. The importance of cellular metabolism in the 
development of cancer is rooted in the early observations 
of Warburg that tumor cells exhibit enhanced glycolytic 
activity (i.e. the “Warburg effect”) [22]. This phenomenon 
has been receiving a great deal of renewed attention [23-
26]. 
Cancer cells undergo marked changes in metabolic 
activity in order to sustain their malignant phenotypes 
(Figure 1). One such set of changes is the up-regulation 
of the expression of enzymes in the glycolytic pathway, 
thus accelerating many of the reactions in this pathway. 
However, importantly, the penultimate step in glycolysis, 
the conversion of phosphoenolpyruvate to pyruvate, 
catalyzed by the enzyme pyruvate kinase, is attenuated 
(rather than accelerated) in cancer cells [24,25]. This occurs 
as a result of the tyrosine phosphorylation of a specific 
isoform of pyruvate kinase (M2) that is preferentially 
expressed in cancer cells, as well as in embryonic cells, 
but not in differentiated cells [24,25,27]. The net outcome 
of this attenuation is that pyruvate is generated through 
a unique enzymatic mechanism that is uncoupled from 
ATP production and involves the phosphorylation of 
phosphoglycerate mutase by phosphoenolpyruvate 
[26]. Pyruvate, when produced through this “alternative 
glycolytic pathway”, is converted primarily to lactic acid, 
rather than acetyl-CoA for citrate synthesis, with citrate 
then normally entering the citric acid cycle. The increased 
production of lactic acid by cancer cells, as a result of 
these changes in the glycolytic pathway, was a seminal 
observation of Warburg’s nearly 80 years ago, and reflects 
one aspect of the metabolic remodeling that frequently 
accompanies cellular transformation.
A second major set of changes in cancer metabolism 
that helps to accommodate the alterations in the glycolytic 
pathway, results in a shift to increased rates of glutamine 
metabolism. This occurs through the accelerated 
hydrolysis of glutamine to glutamate, as catalyzed by 
mitochondrial glutaminase activity, and the subsequent 
conversion of glutamate to α-ketoglutarate, catalyzed by 
glutamate dehydrogenase. The enhanced production of 
α-ketoglutarate that is the outcome of elevated glutamine 
metabolism helps to maintain the citric acid cycle in cancer 
cells, particularly given the loss of the input from pyruvate 
figure 1:  metabolic remodeling of cancer cells  schematic highlights key differences in many cancer cells compared to 
normal tissue.  Normal cells use glycolysis prior to respiration in the mitochondria (yellow) and complete breakdown of glucose by the 
tricarboxylic acid (TCA) cycle (green).  In cancer cells, glycolysis becomes the primary mode of glucose metabolism resulting in lactate and 
its secretion.  The M2 isoform of pyruvate kinase (PKM2) becomes tyrosine phosphorylated and attenuates pyruvate acetyl-CoA conversion 
while glutaminolysis provides the cancer cell with an alternate source of biosynthetic precursors, fueling the TCA cycle with glutamine-derived 
α-keto-glutarate.  The anti-tumor drug 968 inhibits glutamine metabolism by inhibiting the enzyme glutaminase (GLS).
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that is generated via glycolysis in normal (non-cancerous) 
cells. Metabolic flux experiments using  13C-NMR have 
demonstrated that while proliferating cancer cells exhibit a 
pronounced Warburg effect, their citric acid cycle remains 
intact and serves to replenish metabolic intermediates 
necessary for the production of NADPH for fatty acid 
synthesis, to provide the carbon source for nucleotide 
synthesis as well as for the production of asparagine and 
arginine, and to serve as a major anaplerotic source of 
oxaloacetate [23,28]. Thus, cancer cells are often referred 
to as being “glutamine addicted”, as they typically are 
extremely sensitive to glutamine deprivation and hence 
cannot proliferate in cell culture without it. 
Our recent work suggests that the glutamine 
addiction of cancer cells is enabled by the activation 
of glutaminase, which catalyzes one of the key steps in 
glutamine metabolism, as an outcome of post-translational 
modifications. This discovery stemmed from the screening 
for small molecule inhibitors that blocked the ability of 
different constitutively active Rho GTPases, as well as 
oncogenic Dbl, to transform fibroblasts. These efforts led 
to our identification of a small molecule inhibitor of Rho 
GTPase-dependent cellular transformation, designated 
as 968, that is a member of the benzophenanthridinone 
family. As shown in Figure 2, 968 was very effective at 
blocking Dbl-induced focus formation, whereas very 
subtle changes in the molecule, such as the removal of 
bromine from the phenyl ring (i.e. molecule 335 in Figure 
2), caused it to be ineffective at inhibiting transformation. 
We went on to show that the target of 968 is glutaminase 
C (GAC), a specific carboxy-terminal splice variant form 
of kidney-type glutaminase (GLS1), which is one of two 
known mammalian glutaminase enzymes (the other being 
the “liver-type” or GLS2), found in kidney and a variety 
of other tissues including a number of types of cancer cells 
[29]. We then demonstrated that targeting GAC, either 
through the use of the small molecule inhibitor 968 or by 
RNAi, blocks the growth and invasive activity of various 
human breast cancer cells, as well as a variety of other 
types of human cancer cell lines.
We will now consider some of the outstanding 
questions regarding the regulation of glutaminase activity 
in cancer cells, and how intervention at the level of this 
enzyme and glutamine metabolism might offer new 
avenues for therapeutic intervention against cancer. 
reGulAtion of GlutAminAse in 
trAnsformed cells And cAncer 
cells
There are two obvious mechanisms by which an 
enzymatic activity might be increased in cancer cells; one 
is by up-regulating the expression of the enzyme such that 
its protein levels in cancer cells greatly exceed the levels 
in non-transformed differentiated cells, and the other is 
by directly regulating the enzyme’s activity. Indeed, 
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figure 2:  Glutaminase inhibition prevents rho GtPase driven transformation. NIH-3T3 mouse fibroblasts in 10 cm plates were 
transfected with pZIPneoDbl and allowed to grow for 10 days in the presence of DMSO only (control), 5 µM of the inactive 968 analog 335 
(CAS registry number 22949-42-4), or 5 µM 968 (CAS registry number 311795-38-7), after which the plates were fixed and stained with crystal 
violet.  Structures of the inactive and active compounds are shown below treated cell samples.Oncotarget 2010; 1:  734 - 740 737 www.impactjournals.com/oncotarget
it was reported by Gao et al. that glutaminase (GAC) 
expression was up-regulated in a c-Myc-dependent 
manner in human B lymphoma and prostate cancer cells 
[30]. Similarly, we found that the expression levels of 
GAC were significantly increased in MDA-MB231 cells, 
a highly aggressive breast cancer cell line, compared to 
normal mammary epithelial cells [21]. However, at least 
in the case of MDA-MB231 cells, the up-regulation 
of GAC cannot fully account for the changes in its 
enzymatic activity that we observed. Specifically, whereas 
the basal levels of activity for recombinant preparations 
of GAC are typically < 5% of the activity measured in 
the presence of 50-100 mM inorganic phosphate, which 
serves as an allosteric activator of the enzyme, the basal 
activity measured in mitochondrial fractions from these 
breast cancer cells is generally 30-50% of the maximal 
activity assayed in the presence of inorganic phosphate. 
Thus, the basal glutaminase activity is disproportionately 
increased in MDA-MB231 cells compared to the basal 
activity for the purified recombinant protein. Moreover, 
glutaminase activity is markedly increased in different 
transformed fibroblasts and in other cancer cells compared 
to their non-transformed counterparts, in the absence 
of any apparent changes in the expression levels of the 
enzyme. A good example comes from our studies of Dbl-
transformed NIH-3T3 cells where the basal glutaminase 
activity is 5-10 fold higher than the corresponding activity 
measured  in  control  (non-transformed)  fibroblasts, 
whereas the enzyme activities for these two sets of cells 
were essentially identical when assayed in the presence 
of 100 mM inorganic phosphate. Thus, the total levels of 
glutaminase are essentially equivalent in Dbl-transformed 
cells compared to control fibroblasts; however, the basal 
enzyme activity is significantly greater in the transformed 
cells. The same was found to be true in the human breast 
cancer SKBR3 cell line.
An even more compelling indication that basal 
glutaminase activity is increased in transformed/cancer 
cells, independent of changes in the expression levels 
of the enzyme, comes from experiments where we 
ectopically expressed GAC in Dbl-transformed cells and 
normal fibroblasts. We found that ectopically expressed, 
epitope-tagged GAC, when immunoprecipitated from 
transformed  cells,  exhibited  significantly  higher  basal 
enzyme activity compared to an equivalent amount of the 
epitope-tagged enzyme immunoprecipiated from normal 
cells. These findings provided us with our first clue that 
glutaminase  might  be  post-translationally  modified  in 
transformed/cancer  cells  and  that  the  modification(s) 
could explain the activation of its (basal) enzymatic 
activity, thereby providing a molecular link to the elevated 
glutamine metabolism exhibited by these cells.
how is GlutAminAse ActivAted in 
trAnsformed/cAncer cells?
An important clue regarding how GAC is activated in 
transformed/cancer cells came from our finding that when 
the immunoprecipitated enzyme from Dbl-transformed 
cells was first treated with alkaline phosphatase prior to 
assaying its enzymatic activity, virtually all of its basal 
activity (but not the inorganic phosphate-stimulated 
activity) was eliminated. This suggested that GAC is 
phosphorylated in transformed/cancer cells and that this 
is responsible for the marked increase in its basal activity. 
Transformed cells and cancer cells treated with 968 did 
not exhibit elevated basal glutaminase activity. Kinetic 
studies  performed  using  purified  recombinant  GAC 
indicated that 968 is neither competing with the binding 
of substrate (glutamine) nor inorganic phosphate (21). 
Apparently, 968 acts in an allosteric manner to prevent 
the activation of GAC in cells by blocking the post-
translational modification(s) responsible for activating the 
enzyme. This would explain how the inhibitory effects 
of 968 are sustained through the isolation of transformed 
cells and cancer cells through the washes that are 
performed to isolate mitochondrial fractions. Moreover, 
by  blocking  a  post-translational  modification(s)  that 
occurs predominantly in transformed/cancer cells, and not 
in normal (non-cancerous) cells, it is easier to understand 
why this small molecule inhibitor shows such specificity 
for transformed/cancer cells in terms of its inhibitory 
effects.
The role of NfκB
An important remaining question concerns how 
the hyper-activation of Rho GTPase-signaling events, 
which leads to cellular transformation and the induction 
of malignant phenotypes in various human cancer cells, 
results in the activation of a mitochondrial metabolic 
enzyme. Because the increase in basal glutaminase 
activity occurred in cells transformed by different Rho 
GTPases (i.e. Cdc42, Rac, and RhoC), and given that each 
of these GTPases signal through distinct groups of target/
effector proteins, we examined whether NFκB might be 
involved, as it had been reported that a number of Rho 
GTPases were capable of activating this transcription 
factor [31,32]. In addition, NFκB was shown to be 
essential for Dbl-induced transformation and has been 
implicated in a variety of human cancers, in particular 
breast cancer [33,34], making it an especially attractive 
candidate given that a number of different breast cancer 
cells lines were highly sensitive to 968. In fact, we 
discovered that blocking NFκB activation with a small 
molecule that inhibits the degradation of its negative 
regulator IKBα, as well as knocking-down the expression 
of the large NFκB subunit, p65/RelA, by RNAi markedly 
inhibited the activation of glutaminase in Dbl-transformed 
cells and in breast cancer cells. However, this raises one 
of a number of pressing questions for the future, namely, 
how does NFκB activate basal glutaminase activity in Oncotarget 2010; 1:  734 - 740 738 www.impactjournals.com/oncotarget
transformed/cancer cells? 
Questions for the future
NFκB is a well-known transcription factor that has 
been linked to a wide range of cellular and biological 
activities including the survival and migration of cancer 
cells. In the absence of growth factor- or cytokine-signaling 
activities, NFκB remains in the cytosol associated with a 
negative regulatory protein IκBα. However, when growth 
factor/cytokine-signaling pathways are activated, IκBα is 
phosphorylated and degraded, thereby freeing NFκB to 
translocate to the nucleus and promote the expression of a 
number of genes. While the increases in basal glutaminase 
activity in transformed/cancer cells are dependent on 
NFκB activity, we know that this is not the result of a 
direct effect of this transcription factor on glutaminase 
expression. Indeed, even the enzymatic activity of 
ectopically expressed GAC is markedly increased in 
Dbl-transformed cells and this activation is dependent 
on NFκB. The implication would then be that NFκB is 
up-regulating either the expression of a growth factor (or 
cytokine), a protein kinase, and/or a regulatory protein 
that is essential for the activation of GAC. Recent 2D-gel 
electrophoresis experiments are consistent with the 
idea  that  post-translational  modifications  of  ectopically 
expressed GAC that are unique to transformed/cancer 
cells, are responsible for the activation of the enzyme, 
and that the binding of 968 blocks these activating 
modifications  (J.  Wang,  unpublished  observations). An 
important goal of our future studies will be to identify 
the post-translational modification site(s) that leads to the 
activation of glutaminase in transformed/cancer cells, as 
this will hopefully provide clues toward understanding the 
mechanism by which NFκB regulates enzyme activity.
Of course, a number of additional important 
questions will need to be addressed. In particular, we 
would like to obtain structural information that sheds some 
light on how glutaminase is activated in transformed/
cancer cells. It has been suggested that GLS1 undergoes 
an oligomeric transition from an inactive dimer to an 
active tetramer upon the binding of inorganic phosphate 
[35]. Does phosphorylation and/or some other type of 
post-translational modification of GAC help to promote 
the dimer-to-tetramer transition in cancer cells? If so, is 
this transition being driven by a combination of the post-
translational modification of the enzyme and the binding 
of inorganic phosphate or another metabolite that might 
act as an activator in cells? How does the binding of the 
small molecule 968 block this activation event? Thus 
far, we have not found 968 to inhibit the ability of high 
concentrations of inorganic phosphate (i.e. 100 mM) to 
induce the dimer-to-tetramer transition in GAC. However, 
968 might still prevent the enzyme from undergoing 
this transition in response to lower levels of inorganic 
phosphate or a specific metabolite, as might otherwise 
occur in cancer cells not treated with this small molecule 
inhibitor. These are questions that are now being actively 
pursued in our laboratory.
imPlicAtions for future 
therAPeutic strAteGies
The fact that inhibiting the activation of glutaminase 
in transformed/cancer cells with the small molecule 
968  has  specific  effects  on  the  growth,  migration  and 
invasive activity of these cells, without affecting the 
growth or morphology of their non-transformed cellular 
counterparts, offers exciting new possibilities for 
therapeutic intervention. The conventional thinking has 
been that the over-expression of growth factor receptors 
and their signaling partners gives rise to excessive 
signaling events that result in malignant transformation 
and cancer progression [36-38]. Consequently, a number 
of therapeutic strategies have been directed at inhibiting 
receptor activation and function, both through the use of 
tyrosine kinase inhibitors and monoclonal antibodies [39-
43]. Some of these strategies have shown some promise, 
although many of these cancers become resistant to such 
treatments, and there remains a need for the identification 
of additional druggable targets that will permit multi-
pronged strategies for therapeutic intervention against a 
number of human malignancies. The ability of the small 
molecule 968 to alter the unique metabolic fluxes that are 
necessary for cancer cells to satisfy their biosynthetic and 
energetic requirements opens the door to novel approaches 
for intervention against the malignant state. In this regard 
it is especially noteworthy that 968 blocks the activation of 
a metabolic enzyme that is selectively activated in cancer. 
Thus far, the early studies in mouse xenograft models show 
that the intraperitoneal injection of the small molecule 
968 shrinks the tumors in these animals without obvious 
adverse effects (21). Therefore, targeting glutaminase as 
well as other enzymes responsible for the metabolic re-
programming of cancer cells could offer some exciting 
and  highly  specific  strategies  for  intervention  against 
malignancies manifesting glutamine addiction.
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